X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-04-09 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $40.12 | -25,000 | 2,705,438 | -1% | -$1,002,888 | ||||||
| D | 2026-04-09 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $40.24 | -133,789 | 411,855 | -25% | -$5,383,388 | |||||
| M | 2026-02-18 | ACET | Adicet Bio, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $7.17 | +223,596 | 1,182,624 | +23% | +$1,603,934 | |||||
2026-04-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $77.95 | -500 | 78,890 | -1% | -$38,975 | ||||||
2026-04-09 | KNSA | Kiniksa Pharmaceuticals International, Plc | Megna Michael R | CHIEF ACCOUNTING OFFICER | S - Sale | $46.69 | -6,625 | 27,418 | -19% | -$309,321 | ||||||
2026-04-09 | KNSA | Kiniksa Pharmaceuticals International, Plc | Moat Ross | COO | S - Sale | $46.69 | -1,703 | 12,029 | -12% | -$79,513 | ||||||
| D | 2026-04-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $569.28 | -9,500 | 679,872 | -1% | -$5,408,194 | |||||
| D | 2026-04-09 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $104.48 | -3,093 | 65,604 | -5% | -$323,164 | |||||
2026-04-09 | BLTE | Belite Bio, Inc | Lin Yu-Hsin | CEO | S - Sale | $181.45 | -9,200 | 170,934 | -5% | -$1,669,339 | ||||||
2026-04-09 | BLTE | Belite Bio, Inc | Chen Wan-Shan | Dir | S - Sale | $180.43 | -1,100 | 9,096 | -11% | -$198,473 | ||||||
2026-04-09 | BLTE | Belite Bio, Inc | Chuang Hao-Yuan | CFO | S - Sale | $181.50 | -6,200 | 93,800 | -6% | -$1,125,303 | ||||||
2026-04-10 | XNCR | Xencor Inc | Cornelissen Bart Jan | SVP, CFO | S - Sale | $12.29 | -3,499 | 75,898 | -4% | -$42,990 | ||||||
2026-04-09 | WHWK | Whitehawk Therapeutics, Inc. | Lennon David James | CEO | S - Sale | $3.38 | -14,500 | 518,622 | -3% | -$49,010 | ||||||
| M | 2026-04-09 | MLTX | Moonlake Immunotherapeutics | Bodenstedt Matthias | CFO | S - Sale | $18.95 | -87,795 | 1,188,510 | -7% | -$1,663,935 | |||||
2026-04-08 | ROIV | Roivant Sciences Ltd. | Humes Jennifer | Chief Accounting Officer | S - Sale | $28.37 | -13,538 | 84,191 | -14% | -$384,073 | ||||||
| D | 2026-04-08 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $311.59 | -332 | 318,370 | 0% | -$103,448 | |||||
| D | 2026-04-09 | DNTH | Dianthus Therapeutics, Inc. /De/ | Savitz Ryan | EVP, CFO, CBO | S - Sale+OE | $89.84 | -8,224 | 0 | -100% | -$738,844 | |||||
| D | 2026-04-08 | CRNX | Crinetics Pharmaceuticals, Inc. | Knight Jeff E. | Chief Dev., Operating Officer | S - Sale+OE | $40.10 | -85,163 | 105,289 | -45% | -$3,415,036 | |||||
| D | 2026-04-09 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $577.89 | -10,000 | 18,876 | -35% | -$5,778,922 | |||||
| D | 2026-04-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $577.88 | -9,500 | 679,872 | -1% | -$5,489,819 | |||||
2026-04-10 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | Pres, 10% | P - Purchase | $4.90 | +10,000 | 7,562,140 | 0% | +$48,950 | ||||||
2026-04-09 | PHVS | Pharvaris N.V. | Modig Berndt | CEO | S - Sale | $27.74 | -23,333 | 1,092,084 | -2% | -$647,281 | ||||||
| M | 2026-04-07 | ACET | Adicet Bio, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $6.45 | -104,658 | 923,286 | -10% | -$674,847 | |||||
| D | 2026-04-08 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $580.45 | -9,500 | 679,872 | -1% | -$5,514,306 | |||||
2026-04-08 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Chief Development Officer | S - Sale | $34.90 | -360 | 286,516 | 0% | -$12,564 | ||||||
| M | 2026-04-08 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | Pres, 10% | P - Purchase | $5.47 | +15,000 | 7,552,140 | 0% | +$82,000 | |||||
| M | 2026-04-06 | WHWK | Whitehawk Therapeutics, Inc. | Lennon David James | CEO | S - Sale | $3.45 | -260,427 | 533,122 | -33% | -$899,538 | |||||
2026-04-06 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | S - Sale | $20.45 | -3,017 | 117,602 | -3% | -$61,692 | ||||||
| D | 2026-04-07 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $40.97 | -20,000 | 2,231 | -90% | -$819,400 | |||||
2026-04-06 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale | $20.45 | -1,224 | 23,366 | -5% | -$25,028 | ||||||
2026-04-06 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale | $20.45 | -2,653 | 1,122,626 | 0% | -$54,249 | ||||||
2026-04-06 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale | $20.45 | -853 | 31,705 | -3% | -$17,442 | ||||||
2026-04-06 | ZLAB | Zai Lab Ltd | Amado Rafael | See Remarks | S - Sale | $20.45 | -2,739 | 57,022 | -5% | -$56,007 | ||||||
| D | 2026-04-06 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $69.45 | -2,265 | 105,212 | -2% | -$157,293 | |||||
| D | 2026-04-06 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $18.01 | -3,970 | 3,622 | -52% | -$71,508 | |||||
| D | 2026-04-06 | KNSA | Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | COB, CEO | S - Sale+OE | $50.01 | -7,278 | 237,763 | -3% | -$363,973 | |||||
| D | 2026-04-06 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $163.22 | -10,699 | 535,109 | -2% | -$1,746,336 | |||||
| D | 2026-04-06 | KNSA | Kiniksa Pharmaceuticals International, Plc | Moat Ross | COO | S - Sale+OE | $48.58 | -2,367 | 13,732 | -15% | -$114,989 | |||||
| D | 2026-04-06 | KNSA | Kiniksa Pharmaceuticals International, Plc | Quart Barry D | Dir | S - Sale+OE | $50.00 | -6,901 | 12,546 | -35% | -$345,050 | |||||
| D | 2026-04-07 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $564.01 | -9,500 | 679,872 | -1% | -$5,358,116 | |||||
| D | 2026-04-06 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $103.77 | -30,000 | 324,879 | -8% | -$3,113,231 | |||||
| D | 2026-04-06 | NUVB | Nuvation Bio Inc. | Wentworth Kerry | Chief Regulatory Officer | S - Sale+OE | $4.52 | -200,000 | 53,000 | -79% | -$903,560 | |||||
| D | 2026-04-07 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $65.11 | -4,500 | 153,902 | -3% | -$292,985 | |||||
| D | 2026-04-07 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $22.20 | -2,709 | 62,836 | -4% | -$60,140 | |||||
| D | 2026-04-07 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale+OE | $22.20 | -1,030 | 27,865 | -4% | -$22,866 | |||||
2026-04-07 | LPCN | Lipocine Inc. | Higuchi John W. | Dir | P - Purchase | $2.03 | +40,000 | 203,797 | +24% | +$81,200 | ||||||
| D | 2026-04-06 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $33.00 | -10,000 | 37,500 | -21% | -$330,000 | |||||
| D | 2026-04-06 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $558.40 | -10,000 | 18,876 | -35% | -$5,583,999 | |||||
| D | 2026-04-06 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $558.41 | -9,500 | 679,872 | -1% | -$5,304,905 | |||||
| M | 2026-04-02 | ALNY | Alnylam Pharmaceuticals, Inc. | McLaughlin Melissa | CHRO | S - Sale | $325.92 | -3,910 | 9,443 | -29% | -$1,274,343 | |||||
| M | 2026-04-02 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | Pres, 10% | P - Purchase | $6.14 | +25,000 | 7,537,140 | 0% | +$153,398 | |||||
2026-04-06 | ALKS | Alkermes Plc. | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S - Sale | $34.57 | -2,034 | 233,592 | -1% | -$70,315 | ||||||
2026-04-06 | LPCN | Lipocine Inc. | Higuchi John W. | Dir | P - Purchase | $2.05 | +123,000 | 163,797 | +301% | +$252,150 | ||||||
2026-04-06 | LPCN | Lipocine Inc. | Patel Mahesh V. | CEO | P - Purchase | $2.03 | +25,000 | 160,679 | +18% | +$50,750 | ||||||
| M | 2026-04-02 | BCYC | Bicycle Therapeutics Plc | Hannay Michael Charles Ferguson | CHIEF PROD, SUPPLY CHAIN OFF | S - Sale | $4.93 | -1,772 | 96,136 | -2% | -$8,736 | |||||
| M | 2026-04-02 | BCYC | Bicycle Therapeutics Plc | Thompson Travis Alvin | CFO | S - Sale | $4.93 | -901 | 65,364 | -1% | -$4,438 | |||||
| M | 2026-04-02 | BCYC | Bicycle Therapeutics Plc | Perry Jennifer Scott | COO | S - Sale | $4.94 | -1,408 | 92,464 | -1% | -$6,962 | |||||
| M | 2026-04-02 | BCYC | Bicycle Therapeutics Plc | Lee Kevin | CEO | S - Sale | $4.94 | -7,683 | 611,313 | -1% | -$37,964 | |||||
| M | 2026-04-02 | BCYC | Bicycle Therapeutics Plc | Skynner Michael | CHIEF SCIENTIFIC OFFICER | S - Sale | $4.94 | -2,404 | 159,562 | -1% | -$11,877 | |||||
2026-04-06 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale | $13.43 | -4,170 | 154,554 | -3% | -$56,014 | ||||||
2026-04-02 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $4.81 | -24,925 | 401,891 | -6% | -$119,889 | ||||||
2026-04-02 | PTCT | Ptc Therapeutics, Inc. | Golden Lee Scott | EVP, CHIEF MEDICAL OFFICER | S - Sale | $67.99 | -829 | 79,115 | -1% | -$56,364 | ||||||
| D | 2026-04-02 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $561.37 | -9,500 | 679,872 | -1% | -$5,333,053 | |||||
| D | 2026-04-02 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $561.50 | -10,000 | 18,876 | -35% | -$5,614,984 | |||||
| D | 2026-04-02 | AGIO | Agios Pharmaceuticals, Inc. | Burns James William | GC | S - Sale+OE | $34.71 | -3,280 | 49,306 | -6% | -$113,849 | |||||
| D | 2026-04-02 | AGIO | Agios Pharmaceuticals, Inc. | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | $34.71 | -2,940 | 80,277 | -4% | -$102,047 | |||||
| D | 2026-04-02 | AGIO | Agios Pharmaceuticals, Inc. | Jones Cecilia | CFO | S - Sale+OE | $34.71 | -3,141 | 54,998 | -5% | -$109,024 | |||||
| D | 2026-04-02 | AGIO | Agios Pharmaceuticals, Inc. | Milanova Tsveta | Chief Commercial Officer | S - Sale+OE | $34.71 | -3,262 | 46,829 | -7% | -$113,224 | |||||
| D | 2026-04-02 | AGIO | Agios Pharmaceuticals, Inc. | Viswanadhan Krishnan | Chief Corp Dev, Strategy | S - Sale+OE | $34.71 | -2,959 | 10,282 | -22% | -$102,707 | |||||
2026-04-06 | ALT | Altimmune, Inc. | Gill John | Dir | P - Purchase | $3.41 | +9,200 | 21,700 | +74% | +$31,350 | ||||||
| D | 2026-04-02 | AGIO | Agios Pharmaceuticals, Inc. | Goff Brian | CEO | S - Sale+OE | $34.71 | -19,068 | 184,508 | -9% | -$661,850 | |||||
2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $49.33 | -15,000 | 627,540 | -2% | -$739,912 | ||||||
| D | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Officer | S - Sale+OE | $50.00 | -7,958 | 0 | -100% | -$397,900 | |||||
| D | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $49.34 | -7,500 | 97,994 | -7% | -$370,076 | |||||
2026-04-02 | IMNM | Immunome Inc. | Higgins Jack | Chief Scientific Officer | S - Sale | $21.64 | -9,438 | 25,000 | -27% | -$204,238 | ||||||
| D | 2026-04-02 | IMNM | Immunome Inc. | Rosett Max | CFO | S - Sale+OE | $21.92 | -65,000 | 54,037 | -55% | -$1,424,916 | |||||
| D | 2026-04-02 | WHWK | Whitehawk Therapeutics, Inc. | Lennon David James | CEO | S - Sale+OE | $3.48 | -26,858 | 793,549 | -3% | -$93,466 | |||||
| D | 2026-04-02 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | S - Sale+OE | $20.39 | -9,614 | 120,619 | -7% | -$196,029 | |||||
| D | 2026-04-02 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale+OE | $20.39 | -4,194 | 24,590 | -15% | -$85,516 | |||||
| D | 2026-04-02 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $20.39 | -5,576 | 1,125,279 | 0% | -$113,695 | |||||
| D | 2026-04-02 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale+OE | $20.39 | -5,199 | 32,558 | -14% | -$106,008 | |||||
| D | 2026-04-02 | ZLAB | Zai Lab Ltd | Amado Rafael | See Remarks | S - Sale+OE | $20.39 | -9,910 | 59,761 | -14% | -$202,065 | |||||
2026-04-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $23.88 | -10,000 | 39,744 | -20% | -$238,801 | ||||||
2026-04-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $5.99 | -16,667 | 1,209,840 | -1% | -$99,859 | ||||||
2026-04-01 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale | $69.04 | -52,003 | 62,874 | -45% | -$3,590,243 | ||||||
2026-04-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $190.50 | -6,000 | 384,682 | -2% | -$1,143,010 | ||||||
2026-04-02 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Dir | P - Purchase | $2.10 | +713,800 | 3,511,896 | +26% | +$1,498,980 | ||||||
| D | 2026-04-02 | CAPR | Capricor Therapeutics, Inc. | Sabar Karimah Es | Dir | S - Sale+OE | $32.00 | -7,529 | 0 | -100% | -$240,928 | |||||
2026-04-01 | VRTX | Vertex Pharmaceuticals Inc / Ma | Liu Joy | EVP, GC | S - Sale | $449.17 | -978 | 21,833 | -4% | -$439,288 | ||||||
| D | 2026-04-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $105.21 | -11,430 | 85,533 | -12% | -$1,202,527 | |||||
2026-04-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $32.66 | -1,838 | 38,864 | -5% | -$60,029 | ||||||
2026-04-01 | DYN | Dyne Therapeutics, Inc. | Lucera Erick | CFO | S - Sale | $18.64 | -5,727 | 125,373 | -4% | -$106,751 | ||||||
| D | 2026-04-01 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale+OE | $164.63 | -88,060 | 106,810 | -45% | -$14,497,651 | |||||
| D | 2026-04-01 | BIOA | Bioage Labs, Inc. | Rubin Paul D | Chief Medical Officer | S - Sale+OE | $17.81 | -8,820 | 0 | -100% | -$157,084 | |||||
2026-04-01 | EBS | Emergent Biosolutions Inc. | Williams Paul Anthony | SVP, Products Business | S - Sale | $8.44 | -4,000 | 62,681 | -6% | -$33,760 | ||||||
2026-04-01 | REGN | Regeneron Pharmaceuticals, Inc. | Ryan Arthur F | Dir | S - Sale | $777.27 | -100 | 17,603 | -1% | -$77,727 | ||||||
| M | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale | $16.96 | -15,959 | 17,338 | -48% | -$270,593 | |||||
| D | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $16.00 | -679 | 3,622 | -16% | -$10,864 | |||||
| D | 2026-04-01 | ERAS | Erasca, Inc. | Garner Ebun | GC | S - Sale+OE | $16.40 | -80,000 | 25,076 | -76% | -$1,312,000 | |||||
| M | 2026-03-31 | ADCT | Adc Therapeutics Sa | Redmile Group, LLC | 10% | S - Sale | $3.34 | -5,880,415 | 22,932,028 | -20% | -$19,636,340 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |